Yttrium-90

Yttrium-90
General
Name, symbol Yttrium-90,90Y
Neutrons 51
Protons 39
Nuclide data
Half-life 64.1 h

Yttrium-90, 90
Y
, is a medically significant isotope of yttrium.[1] Yttrium-90 has a wide and valuable use in radiation therapy to treat cancer.[2]

Decay

90
Y
 undergoes β− decay to zirconium-90 with a half-life of 64.1 hours[3] and a decay energy of 2.28 MeV.[4] It also produces 0.01% 1.7 MeV[5] photons along the way. Interaction of the emitted electrons with matter can lead to Bremsstrahlung radiation.

Production

Yttrium-90 is a decay product of strontium-90 which makes up about 5% of the nuclear daughter isotopes when uranium is fissioned.[6] Yttrium-90 is produced by chemical high-purity separation from strontium-90, a fission product of uranium in nuclear reactors.[7]

Clinical Application

90Y plays a significant role in the treatment of hepatocellular carcinoma (HCC) and other liver cancers. Trans-arterial radioembolization is a procedure performed by interventional radiologists in which microspheres are impregnated with 90Y and injected into the arteries supplying the tumor.[8] Radioembolization with 90Y significantly increases time-to-progression (TTP) of HCC,[9] has a tolerable adverse event profile, and improves patient quality of life more than do similar therapies.[10]

See also

References

  1. ↑ Vincent T. DeVita; Theodore S. Lawrence; Steven A. Rosenberg; Robert A. Weinberg; Ronald A. DePinho (1 April 2008). DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology. Lippincott Williams & Wilkins. pp. 2507–. ISBN 978-0-7817-7207-5. Retrieved 9 June 2011.
  2. ↑ Arkadiy Kheyfits (October 2010). "Yttrium-90 Radioembolization". Radiology Today. Retrieved 2012-10-23.
  3. ↑ "Y-90 Handling Precautions" (PDF). Retrieved 2015-07-15.
  4. ↑ "Table of Isotopes decay data". The Lund/LBNL Nuclear Data Search. February 1999. Retrieved 2012-10-23.
  5. ↑ Rault, E.; Vandenberghe, S.; Staelens, S.; Lemahieu, I. (2009). Optimization of Yttrium-90 Bremsstrahlung Imaging with Monte Carlo Simulations. 4th European Conference of the International Federation for Medical and Biological Engineering. 22. pp. 500–504. Retrieved 21 October 2013.
  6. ↑ "Strontium | Radiation Protection | US EPA". EPA. 24 April 2012. Retrieved 2012-10-23.
  7. ↑ "PNNL: Isotope Sciences Program - Yttrium-90 Production". PNNL. February 2012. Retrieved 2012-10-23.
  8. ↑ Kallini JR, Gabr A, Salem R, Lewandowski RJ. (02 April 2016.). "Trans-arterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma". Adv Ther. Check date values in: |date= (help)
  9. ↑ Salem R, Gordon AC, Mouli S, Hickey R, Kallini J; et al. (2016 Aug 26). "Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma". Gastroenterology. 151: 1155–1163.e2. PMC 5124387 Freely accessible. PMID 27575820. doi:10.1053/j.gastro.2016.08.029. Check date values in: |date= (help)
  10. ↑ Salem, R. Gilbertsen, M. Butt, Z. Memon, K. Vouche, M. Hickey, R. Baker, T. Abecassis, M. M. Atassi, R. Riaz, A. Cella, D. Burns, J. L. Ganger, D. Benson, A. B., 3rd Mulcahy, M. F. Kulik, L. Lewandowski, R. (2013). "Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization". Clin Gastroenterol Hepatol. 11 (10): 1358–1365.e1. doi:10.1016/j.cgh.2013.04.028.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.